Daniel studied biochemistry at Ulm University, Germany and did his PhD in Alzheimer’s disease research. In February 2018, he started at Boehringer Ingelheim in Analytical Development. His main task was the development of potency assays and especially the implementation of the surface plasmon resonance technology in his lab for customer projects. In 2021 he got a new position as senior scientist in Analytical Development Biologicals developing potency assays for in-house products. His main responsibilities are the development and implementation of new technologies for potency determination.